Literature DB >> 1100305

Pharmacokinetics of indomethacin.

G Alván, M Orme, L Bertilsson, R Ekstrand, L Palmér.   

Abstract

Plasma concentrations of indomethacin have been studied in 5 healthy volunteers after single and multiple doses (25 mg intravenously [iv], 25, 50, and 100 mg orally, 100 mg rectally, and 25 mg three times daily [tid]. In 8 other normal subjects and in 5 patients a 50-mg oral dose of indomethacin was given and the indomethacin concentration was followed from 8 to 32 hr after dosing. All analyses were carried out using a new mass fragmentographic method. After oral and rectal doses the plasma decay of indomethacin was biphasic, and the data were interpreted according to a 2-compartment open model. The half-life of the beta-phase varied between 2.6 and 11.2 hr. The volume of distribution ranged from 0.34 to 1.57 L/kg and the plasma clearance from 0.044 to 0.109 L/kg/hr. There was no evidence of dose-dependent elimination. Indomethacin was rapidly and well absorbed after oral dosing with peak plasma concentrations within 2 hr. Comparison with the area under the curve (AUC) after iv dosing indicated complete bioavailability. The AUC after rectal dosing indicated complete bioavailability, but the rate of absorption was slower than after oral administration. Indomethacin, 25 mg three times daily, was also given for 9 days to the same normal subjects; equilibrium concentrations obtained did not differ significantly (p greater than 0.1) from those predicted from single-dose data in the 5 subjects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1100305     DOI: 10.1002/cpt1975183364

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  50 in total

1.  Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers.

Authors:  J C McElnay; A P Passmore; V L Crawford; J G McConnell; I C Taylor; F S Walker
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

4.  Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin.

Authors:  L O Eriksson; E Wåhlin-Boll; H Liedholm; P Seideman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 6.  Mechanism of action of indomethacin in indomethacin-responsive headaches.

Authors:  Oliver Summ; Stefan Evers
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 7.  Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.

Authors:  J A Vale; T J Meredith
Journal:  Med Toxicol       Date:  1986 Jan-Feb

8.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

9.  Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity.

Authors:  B Bannwarth; P Netter; F Lapicque; P Péré; P Thomas; A Gaucher
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders.

Authors:  N Baber; L D Halliday; W J van den Heuvel; R W Walker; R Sibeon; J P Keenan; T Littler; M L Orme
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.